Fractyl Health (NASDAQ:GUTS) Director Ian Sheffield Purchases 35,000 Shares

Fractyl Health, Inc. (NASDAQ:GUTS) Director Ian Sheffield acquired 35,000 shares of Fractyl Health stock in a transaction dated Wednesday, June 10th. The shares were acquired at an average price of $0.73 per share, with a total value of $25,550.00. Following the completion of the acquisition, the director directly owned 35,000 shares of the company’s stock, valued at approximately $25,550. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Fractyl Health Stock Down 1.1%

Fractyl Health stock traded down $0.01 during midday trading on Thursday, hitting $0.72. 604,328 shares of the stock were exchanged, compared to its average volume of 3,974,317. Fractyl Health, Inc. has a 52-week low of $0.38 and a 52-week high of $2.45. The stock has a market capitalization of $114.85 million, a price-to-earnings ratio of -0.56 and a beta of 2.34. The business’s 50-day moving average price is $0.68 and its 200-day moving average price is $1.08. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.23. On average, research analysts expect that Fractyl Health, Inc. will post -0.6 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on GUTS shares. Canaccord Genuity Group restated a “buy” rating and set a $8.00 price target on shares of Fractyl Health in a report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research report on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.40.

Institutional Trading of Fractyl Health

A number of hedge funds and other institutional investors have recently bought and sold shares of GUTS. Jane Street Group LLC bought a new position in shares of Fractyl Health in the 2nd quarter worth $31,000. FNY Investment Advisers LLC bought a new position in shares of Fractyl Health in the 3rd quarter worth $31,000. Jump Financial LLC bought a new position in shares of Fractyl Health in the 4th quarter worth $57,000. Scientech Research LLC bought a new position in shares of Fractyl Health in the 3rd quarter worth $49,000. Finally, Prelude Capital Management LLC bought a new position in shares of Fractyl Health in the 3rd quarter worth $55,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.